Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies

被引:12
|
作者
Rouhani, Sherin Juliet [1 ]
Yu, Jovian [1 ]
Olson, Daniel [1 ]
Zha, Yuanyuan [1 ]
Pezeshk, Apameh [1 ]
Cabanov, Alexandra [2 ]
Pyzer, Athalia R. [1 ]
Trujillo, Jonathan [1 ]
Derman, Benjamin A. [1 ]
O'Donnell, Peter [1 ]
Jakubowiak, Andrzej [1 ]
Kindler, Hedy L. [1 ]
Bestvina, Christine [1 ]
Gajewski, Thomas F. [1 ,2 ]
机构
[1] Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA
[2] Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA
关键词
COVID-19; immunogenicity; vaccine; immunotherapy; antibody formation; T-lymphocytes; CANCER; PD-1; REGULATOR; EFFICACY;
D O I
10.1136/jitc-2022-004766
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Patients with cancer were excluded from phase 3 COVID-19 vaccine trials, and the immunogenicity and side effect profiles of these vaccines in this population is not well understood. Patients with cancer can be immunocompromised from chemotherapy, corticosteroids, or the cancer itself, which may affect cellular and/or humoral responses to vaccination. PD-1 is expressed on T effector cells, T follicular helper cells and B cells, leading us to hypothesize that anti-PD-1 immunotherapies may augment antibody or T cell generation after vaccination. Methods Antibodies to the SARS-CoV-2 receptor binding domain (RBD) and spike protein were assessed in patients with cancer (n=118) and healthy donors (HD, n=22) after 1, 2 or 3 mRNA vaccine doses. CD4(+) and CD8(+) T cell reactivity to wild-type (WT) or B.1.617.2 (delta) spike peptides was measured by intracellular cytokine staining. Results Oncology patients without prior COVID-19 infections receiving immunotherapy (n=36), chemotherapy (n=15), chemoimmunotherapy (n=6), endocrine or targeted therapies (n=6) and those not on active treatment (n=26) had similar RBD and Spike IgG antibody titers to HDs after two vaccinations. Contrary to our hypothesis, PD-1 blockade did not augment antibody titers or T cell responses. Patients receiving B-cell directed therapies (n=14) including anti-CD20 antibodies and multiple myeloma therapies had decreased antibody titers, and 9/14 of these patients were seronegative for RBD antibodies. No differences were observed in WT spike-reactive CD4(+) and CD8(+) T cell generation between treatment groups. 11/13 evaluable patients seronegative for RBD had a detectable WT spike-reactive CD4(+) T cell response. T cells cross-reactive against the B.1.617.2 variant spike peptides were detected in 31/59 participants. Two patients with prior immune checkpoint inhibitor-related adrenal insufficiency had symptomatic hypoadrenalism after vaccination. Conclusions COVID-19 vaccinations are safe and immunogenic in patients with solid tumors, who developed similar antibody and T cell responses compared with HDs. Patients on B-cell directed therapies may fail to generate RBD antibodies after vaccination and should be considered for prophylactic antibody treatments. Many seronegative patients do develop a T cell response, which may have an anti-viral effect. Patients with pre-existing adrenal insufficiency may need to take stress dose steroids during vaccination to avoid adrenal crisis.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Long-term antibody response following COVID-19 vaccination in patients receiving peritoneal dialysis
    Chinnadurai, Rajkumar
    Ramgobin, Chittesh
    Wu, Henry H. L.
    Hayes, Emma
    Collier, Joanne
    Lewis, David
    Poulikakos, Dimitrios
    SEMINARS IN DIALYSIS, 2022, 35 (06) : 559 - 560
  • [42] Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia
    H. Parry
    G. McIlroy
    R. Bruton
    M. Ali
    C. Stephens
    S. Damery
    A. Otter
    T. McSkeane
    H. Rolfe
    S. Faustini
    N. Wall
    P. Hillmen
    G. Pratt
    S. Paneesha
    J. Zuo
    A. Richter
    P. Moss
    Blood Cancer Journal, 11
  • [43] Antibody responses to second doses of COVID-19 vaccination in lung cancer patients undergoing treatment
    Narita, Daisuke
    Ebina-Shibuya, Risa
    Miyauchi, Eisaku
    Tsukita, Yoko
    Saito, Ryota
    Murakami, Koji
    Kimura, Nozomu
    Sugiura, Hisatoshi
    RESPIRATORY INVESTIGATION, 2023, 61 (02) : 247 - 253
  • [44] Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia
    Parry, H.
    McIlroy, G.
    Bruton, R.
    Ali, M.
    Stephens, C.
    Damery, S.
    Otter, A.
    McSkeane, T.
    Rolfe, H.
    Faustini, S.
    Wall, N.
    Hillmen, P.
    Pratt, G.
    Paneesha, S.
    Zuo, J.
    Richter, A.
    Moss, P.
    BLOOD CANCER JOURNAL, 2021, 11 (07)
  • [45] Antibody Response to COVID-19 Vaccination in Patients with Lung Cancer
    Walter, J.
    Bolt, T.
    Elsner, L.
    Sellmer, L.
    Kahnert, K.
    Mertsch, P.
    Lehnert, N.
    Kauffmann-Guerrero, D.
    Behr, J.
    Tufman, A.
    PNEUMOLOGIE, 2023, 77 : S48 - S48
  • [46] Antibody response to COVID-19 vaccination in patients on chronic hemodialysis
    Choi, Heejung
    Han, Sungdam
    Kim, Ji Su
    Park, Bumhee
    Lee, Min-Jeong
    Shin, Gyu-Tae
    Kim, Heungsoo
    Kim, Kyongmin
    Park, A. -Young
    Shin, Ho-Joon
    Park, Inwhee
    CLINICAL AND EXPERIMENTAL VACCINE RESEARCH, 2023, 12 (03) : 249 - 259
  • [47] ANTIBODY RESPONSE TO COVID-19 VACCINATION IN PATIENTS UNDER DIALYSIS
    Choulitoudi, Vasiliki
    Oikonomaki, Theodora
    Bletsa, Anastasia
    Ampelakiotou, Kleio
    Panagakou, Stella
    Koutroumpas, Georgios
    Palla, Vasiliki
    Panagopoulou, Panagiota
    Adamidis, Konstantinos
    Kogkaki, Eleni
    Dardioti, Vasiliki
    Kousouls, Varvara
    Kolovos, Vasileios
    Pomoni, Stella
    Kontou, Elisavet
    Tsirogianni, Alexandra
    Christodoulidou, Christallenia
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 : I657 - I658
  • [48] Preserved antibody responses to COVID-19 vaccination and lower odds of developing COVID-19 in adults with severe asthma
    Rupani, Hitasha
    Edwards, Diane
    Chaudhuri, Rekha
    Smith, Steven
    Jackson, David J.
    Hearn, Andrew
    Richards, Jennifer
    Moyses, Helen
    Kurukulaaratchy, Ramesh J.
    Haitchi, Hans Michael
    Edwards, Michael R.
    Johnston, Sebastian L.
    Djukanovic, Ratko
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2024, 12 (09):
  • [49] Dynamics of CD4 T Cell and Antibody Responses in COVID-19 Patients With Different Disease Severity
    Koblischke, Maximilian
    Traugott, Marianna T.
    Medits, Iris
    Spitzer, Felicia S.
    Zoufaly, Alexander
    Weseslindtner, Lukas
    Simonitsch, Cara
    Seitz, Tamara
    Hoepler, Wolfgang
    Puchhammer-Stoeckl, Elisabeth
    Aberle, Stephan W.
    Foedinger, Manuela
    Bergthaler, Andreas
    Kundi, Michael
    Heinz, Franz X.
    Stiasny, Karin
    Aberle, Judith H.
    FRONTIERS IN MEDICINE, 2020, 7
  • [50] Antibody and T Cell Immune Responses to SARS-CoV-2 Peptides in COVID-19 Convalescent Patients
    Garanina, Ekaterina
    Hamza, Shaimaa
    Stott-Marshall, Robert J.
    Martynova, Ekaterina
    Markelova, Maria
    Davidyuk, Yuriy
    Shakirova, Venera
    Kaushal, Neha
    Baranwal, Manoj
    Khaertynova, Ilsiyar M.
    Rizvanov, Albert
    Foster, Toshana L.
    Khaiboullina, Svetlana
    FRONTIERS IN MICROBIOLOGY, 2022, 13